Anthoula Koliadi
Specialistläkare vid Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerprecisionsmedicin; Forskargrupp Ingrid Glimelius
- Mobiltelefon:
- 070-971 68 70
- E-post:
- anthoula.koliadi@igp.uu.se
- Besöksadress:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala - Postadress:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
Doktorand vid Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerimmunterapi; Forskargrupp Gustav Ullenhag
- Mobiltelefon:
- 070-971 68 70
- Besöksadress:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala - Postadress:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
- Akademiska meriter:
- Leg.läk., ST-läkare
Mer information visas för dig som medarbetare om du loggar in.
Kort presentation
Jag är överläkare i Gynekologisk onkologi vid Akademiska Sjukhuset i Uppsala. Jag är tumörgruppsansvarig och disputerade 2014 på en avhandling om tumörbiologi och proliferation av cancer.
Nyckelord
- brachyterapi
- cervixcancer
- strålbehandling
- tumörbiologi
Publikationer
Senaste publikationer
- Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer (2024)
- The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients (2024)
- Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors (2023)
- Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes (2022)
- Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors (2021)
Alla publikationer
Artiklar
- Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer (2024)
- The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients (2024)
- Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors (2023)
- Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes (2022)
- Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors (2021)
- Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma. (2020)
- High proliferation is associated with inferior outcome in male breast cancer patients (2013)
- Cyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancer (2010)
- Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort (2010)
- Association between parity, histopathological tumor features and survival in high-grade serous ovarian cancer
Böcker
